BEDFORD, Texas and MEDFORD, Mass., April 19, 2016 /PRNewswire/ -- INVO Bioscience, Inc. (OTC: IVOB), a medical device company who achieved FDA clearance for the first intravaginal culture system, INVOcell™, today announced an agreement with Dr. Kevin Doody for the state of Texas. Dr. Kevin Doody, Medical Director at Centre for Assisted Reproduction will begin offering the INVO Procedure in his current locations initially and will also be working with doctors across the state of Texas to give couples statewide access to the INVO offering.
INVOcell™ is used for fertilization and early embryo development. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory, INVOcell utilizes the women's vagina as a natural incubator. In a recently published clinical trial, the INVOcell procedure combined with a simplified approach to medical management produced pregnancy and live birth rates similar to traditional IVF treatments1.
Dr. Kevin Doody, Medical Director at C.A.R.E in Bedford, where the INVO treatment will be initially offered, commented "This seemingly simple device is truly a disruptive technology. The ability to grow embryos in the patient's vaginal cavity (in-vivo) rather than the large, complex expensive, intensive laboratory setting requiring 24/7 monitoring is tremendously advantageous. We can significantly lower the cost of delivering care by reducing both the need for expensive infrastructure as well as embryologist workload. We combine this with a reduced approach to medication and significantly streamlined monitoring and patient management systems that we call Effortless IVF™. In the future, we anticipate offering the INVO procedure in our Effortless IVF™ facilities for approximately half the current cost of IVF care, with expected similar pregnancy rates to conventional IVF. This will increase the access to advanced fertility care as both geographic and financial barriers will be significantly diminished."
"There are an estimated 620,000 people who have sought fertility care in Texas last year and approximately 13,000 IVF procedures performed per year in the state," noted Katie Karloff, CEO INVO Bioscience. "Under the banner of Effortless IVF, INVO Bioscience and Dr. Kevin Doody will offer a significant value proposition to patients seeking fertility care in Texas. As more physicians are trained on the INVO Procedure, we estimate that over time there will be 10,000 INVO procedures performed per year in Texas. Vaginal culture using INVOcell will disrupt the status quo, delivering patients an alternate form of care that I am confident will appeal to a large segment of the U.S. population who face fertility challenges. INVO Bioscience is committed to rapidly delivering INVOcell through additional partnerships or arrangements and through our own corporate facilities across the U.S."
About the Centre for Assisted Reproduction (CARE)
CARE is an independent facility providing comprehensive medical care for the treatment of infertile patients. Established in 1989, CARE has been providing state-of-the-art fertility treatment to residents of Dallas, Fort Worth, and cities throughout the state of Texas. CARE strives to make it easy for patients to receive cutting-edge treatment and maintains longstanding relationships with all major managed care organizations. CARE offers a comprehensive suite of services including IVF and egg donation. CARE centers are located in Bedford, and Fort Worth Texas. Visit www.embryo.net to learn more. INVOcell™ a registered trademark and patented product of INVO Bioscience, Inc. and is being used under license by CARE.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Kathleen Karloff, CEO
INVO Bioscience, Inc.
978-878-9505 ext. 504
Kevin Doody, MD
Effortless IVF c/o CARE
SOURCE INVO Bioscience, Inc.